Publications (155) Emilio José Sanz Álvarez publications

filter_list

2026

  1. A Comparative Analysis of Fatal Outcomes in 5,370 Geriatric Versus 12,254 Nongeriatric Adult Patients: A Clozapine Study in VigiBase

    The American Journal of Geriatric Psychiatry, Vol. 34, Núm. 4, pp. 591-601

  2. A study in VigiBase of clozapine fatal outcomes in 7874 middle-aged versus 4380 young adults

    Psychiatry Research, Vol. 359, pp. 117037

  3. An international adult guideline for making Clozapine titration safer by using six ancestry-based personalized dosing titrations, CRP, and Clozapine levels

    Chinese Journal of Psychiatry, Vol. 59, Núm. 2, pp. 87-113

  4. Changing your perspective on fatal outcomes in clozapine-treated patients. They do not die of agranulocytosis

    Asian Journal of Psychiatry

  5. Clozapine and Suicide in VigiBase: Most Important Fatal Outcome in Young Males and Differences Between Attempted and Completed Suicide

    Journal of clinical psychopharmacology, Vol. 46, Núm. 1, pp. 5-15

  6. El método Delphi como herramienta de consenso en el diseño de un marco de aplicación de la Inteligencia Artificial en Educación Médica en España.

    Revista Española de Educación Médica, Vol. 7, Núm. 2

  7. The Delphi Method as a Consensus-Building Tool in Designing an Application Framework for Artificial Intelligence in Medical Education in Spain

    SPANISH JOURNAL OF MEDICAL EDUCATION, Vol. 7, Núm. 2

  8. The Feasibility and Quality of the European Prescribing Exam: An International Multicenter Pilot Study Among 3109 Medical Students From 16 Medical Schools

    Clinical Pharmacology and Therapeutics, Vol. 119, Núm. 1, pp. 190-197

  9. The use of generic versus brand names in (clinical) pharmacology education across Europe: a cross-sectional survey

    European Journal of Clinical Pharmacology, Vol. 82, Núm. 3

2025

  1. Barriers and solutions for the European prescribing exam: a qualitative world café study

    European Journal of Clinical Pharmacology, Vol. 81, Núm. 10, pp. 1451-1459

  2. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature

    Expert Opinion on Drug Safety, Vol. 24, Núm. 11, pp. 1301-1311

  3. Clozapine pharmacovigilance in Croatia: Underreporting of specific adverse drug reactions and excellent reporting of suicide attempts: Clozapine Croatia suicide

    Psychiatry Research, Vol. 347

  4. Clozapine-treated patients and myocardial infarction in adults: a pharmacovigilance study in VigiBase interpreted in the context of the literature

    Expert Opinion on Drug Safety

  5. Evaluating the adverse drug reactions to clozapine in populations of children and adolescents: insights from VigiBase data

    European Child and Adolescent Psychiatry, Vol. 34, Núm. 7, pp. 2083-2091

  6. Fatal Outcomes in Use of Clozapine: A VigiBase Study of 6402 Women and 11,222 Men

    Journal of clinical psychopharmacology, Vol. 45, Núm. 6, pp. 547-553

  7. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I A Review of the Pharmacokinetic Literature and Proposed Changes

    Journal of Clinical Psychopharmacology, Vol. 45, Núm. 3, pp. 179-196

  8. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A review of fatal outcomes in US Pharmacovigilance data and proposed changes

    Journal of Clinical Psychopharmacology

  9. The time has come for revising the rules of clozapine blood monitoring in Europe. A joint expert statement from the European Clozapine Task Force

    European Psychiatry, Vol. 68, Núm. 1

2024

  1. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia)

    Schizophrenia Research, Vol. 268, pp. 165-174

  2. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance

    Schizophrenia Research, Vol. 268, pp. 53-59